Trials
4 active
12 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Seasonal Allergic Rhinitis, Adolescents With Moderate-to-severe Atopic Dermatitis, Prurigo Nodularis, Moderate-to-severe Atopic Dermatitis
- Main trialPhase 3
- “This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of SHR-1819 injection in patients with Seasonal Allergic Rhinitis (SAR).”In the company’s words, NCT07688772 on ClinicalTrials.gov
Other drugs for Seasonal Allergic Rhinitis
- StapokibartKeymed Biosciences Co.Ltd · Phase 3
- GR1802Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Phase 3
- Rupatifen FumarateFujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Phase 3
- LP-003Longbio Pharma · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 2/3
- PG-011Prime Gene Therapeutics Co., Ltd. · Phase 3
Coming up4
- DecPhase 3 trial completes · ClinicalTrials.gov
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- Oct 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | A Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | |
| Phase 3Recruiting | Nov 2027 | A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis | |
| Phase 2/3Recruiting | Oct 2028 | Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis | |
| Phase 2Active, not recruiting | Jun 2027 | A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis | |
| Phase 3Completed | 26 Aug 2026 | Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | |
| Phase 2Completed | 15 Sep 2023 | Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | |
| Phase 2Completed | 5 Jun 2025 | A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis | |
| Phase 2Completed | 1 Dec 2025 | A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | |
| Phase 1/2Completed | 22 Nov 2025 | A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis | |
| Phase 1Completed | 10 Dec 2021 | A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects | |
| Phase 1Completed | 27 Oct 2022 | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | |
| Phase 1Completed | 26 Jun 2026 | A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026